Skip To Main Content
Kate Fife on Muck Rack

Kate Fife

As seen in: Future Medicine, EJSO - European Journal of Surgical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Kate Fife’s profile

Articles by Kate Fife

Survival trends of renal cell cancer patients treated with neoadjuvant tyrosine kinase inhibitors before cytoreductive nephrectomies

|
By Sarah Welsh, Grant Stewart, Kate Fife, Manavi Sachdeva
| EJSO - European Journal of Surgical Oncology Verified
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Background: Unfortunately, 30% of patients diagnosed with renal cell cancer (RCC) present with metastatic disease. Cytoreductive nephrectomy (CN) refers to the partial or total resection of the kidney in a patient with metastatic RCC (mRCC). CN is associated with decreased risk of death and a mean increase in overall survival of 6 months.
Open in Who Shared Issue with article?

Treatment of succinate dehydrogenase B-associated renal cancer

|
By Kate Fife, Anne Warren
| bmj.com
Germline mutations in the succinate dehydrogenase B (SDHB) gene are associated with a rare renal cancer with a young age of onset. It is important to raise awareness of this condition as it is dominantly inherited and is associated with other neoplasms. The diagnosis should be considered in patients with renal cancers with distinctive histology. There is little guidance in the literature about how to treat metastatic SDHB renal cancers.
Open in Who Shared Issue with article?
|
By Richard Benson, Kate Fife, Lakshmi Harihar, Amer Durrani, Sarah Jefferies
| secure.jbs.elsevierhealth.com
Open in Who Shared Issue with article?

Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma

|
By Kate Fife, Robert Herd, Susan Lalondrelle, Ruth Plummer
| Future Medicine Verified
Basal cell carcinomas are the most common form of skin cancer. Some develop into advanced cases not suitable for standard therapy. Vismodegib is the first-in-class oral hedgehog pathway inhibitor (which is dysregulated in 90% of basal cell carcinomas), and has demonstrated efficacy for advanced disease in clinical trials. An UK expert panel met to discuss management strategies for adverse events associated with vismodegib (most commonly taste disturbances, muscle cramps and alopecia).
Open in Who Shared Issue with article?
Show More